Author Web | Books | ORCID | Wikipedia | LinkedIn | Op-eds, and Press | Google Scholar | Blogs | Twitter. niazi@niazi.com; +1-312-297-0000.
Coined “biosimilar,” created regulatory guidelines, and established the first biosimilars company in the US, raising over $500 million and securing approval of multiple biosimilars in the US.
Wrote the first and most books on biosimilars and biotechnology.
Created a fast-to-market platform for developing countries.
Wrote the first book on RNA therapeutics; he has developed multiple mRNA vaccines, COVID-19, and multiple autoimmune disorder treatments.
100+ US patents in biotechnology, new drugs, testing methodologies, and novel continuous manufacturing.
He has published 100+ research papers and 60+ books in the technical and literary realms.
Pro bono advisory to the US Senate, the House, the White House, and the heads of state of multiple countries.
Editor of many scientific journals.
· Invited speaker for 500+ talks around the world.
· Academic appointments in six universities.
